Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02130934
Other study ID # 14-0315
Secondary ID
Status Withdrawn
Phase N/A
First received May 1, 2014
Last updated November 10, 2016
Start date May 2014
Est. completion date March 2016

Study information

Verified date November 2016
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This is a non-randomized prospective pilot study in a single academic center with historic controls. This study will compare Cardiac Magnetic Resonance Images (MRI) of patients who have undergone childhood cancer treatment that has cardio-toxic effects to historic controls. The ultimate goal of this study is to develop a safe and effective method for early diagnosis of heart problems in children who are receiving chemotherapy treatments that may be toxic to the heart.


Description:

The following tests and procedures will be performed after consent has been obtained. All tests and procedures noted below are being done for the sole purpose of the study:

Visit 1. Subjects will be asked to complete some questionnaires and answer questions regarding smoking status and use of alcohol or smokeless tobacco. We will also gather basic information such as age, height, weight, gender, ethnicity, race, pertinent medical history as well as collect vital sign information (height, weight, blood pressure, heart and respiratory rate.) Next, subjects will undergo a routine transthoracic echocardiogram.

Visit 2. Following the completion of the echocardiogram, and if selected to take part in the study, subjects will be schedule for a cardiac MRI test within a 3 months period.

When subjects come in for Visit 2, they will receive a 12 lead electrocardiograph (ECG) before the cardiac 3D MRI.

All females who are capable of becoming pregnant, except those who are age 11 and under, will then undergo urine pregnancy testing. If it is found that you are pregnant you will not be allowed to be in the study. If the female is under 18 and a positive pregnancy test result is obtained, we will inform both the participant and her parent/guardian.

Subjects may then be placed in a "simulated" MRI to teach them what it will be like to enter the scanner and also train them on how to breathe calmly and regularly during the scan.

Training will involve the use of a PrimeSense 3D sensor, similar to the cameras used in active videogame systems such as the Xbox Kinect, which will generate a 3D picture of their chest as they breathe. Following this training session, subjects will then undergo cardiac 3D MRI. Study participations will end after this visit.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender Both
Age group 8 Years to 26 Years
Eligibility Inclusion Criteria:

- Childhood cancer treatment which has been completed

- Received anthracyclines as part of childhood cancer treatment, at least 150 mg/m2 as cumulative dose

- normal left ventricular systolic and diastolic functions on echocardiogram

Exclusion Criteria:

- Ongoing cancer treatment

- Pregnancy

- Inability to undergo a cardiac MRI

- Abnormal ventricular systolic or diastolic function on echocardiogram

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
Cardiac 3D MRI


Locations

Country Name City State
United States UK Medical Center Lexington Kentucky
United States University of Kentucky Medical Center Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Majd Makhoul

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ventricular Function Measurement Quantify ventricular functional measurements including strain patterns and measurements using offline processing software that Dr. Fornwalt lab has. Up to 2 years No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04202094 - Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems N/A
Active, not recruiting NCT03336931 - PRecISion Medicine for Children With Cancer
Not yet recruiting NCT05048771 - Fertility and Temporality in Pediatric Oncology
Completed NCT05982379 - Motivation Program for Children With Cancer N/A
Completed NCT04066218 - Sexual Function Screening in Childhood Cancer Survivors
Completed NCT03934060 - Strength Training and ADLs in Childhood Leukemia and Lymphoma Patients N/A
Active, not recruiting NCT03938324 - Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions N/A
Active, not recruiting NCT04032743 - Risk Factors and Treatment Outcome of Oncology Children Hospitalized in the Intensive Care Unit Due to Sepsis
Recruiting NCT04328350 - Social Experiences of Adolescents and Young Adults With Cancer
Not yet recruiting NCT05457153 - Technology-Based Well-Being Process Program (WEBEPROP) for Children and Adolescents in Palliative Care N/A
Recruiting NCT05641961 - Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care N/A
Completed NCT06179914 - Resilience Models in Adolescence and Youth With Cancer in Taiwan
Completed NCT03951246 - Cognitive and Motor Training in Pediatric Posterior Fossa Tumor Survivors N/A
Not yet recruiting NCT04902313 - Cultivating Resilience in Oncology Practice N/A
Completed NCT03160768 - Feasibility of Isolating P16 Expression
Completed NCT02216604 - Exercise in Pediatric Cancer Patient Undergoing Anti-Cancer Treatment N/A
Recruiting NCT03852758 - Green Exercise for Cancer - Creating Opportunities for Survivors N/A
Recruiting NCT06053268 - Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors N/A
Not yet recruiting NCT05754840 - CANnabinoids in Pediatric ONCology Phase 1/Phase 2
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2